The ACTIV-6 trial reported that a “higher” dose of ivermectin failed to shorten symptom duration in a group of patients with mild to moderate severity COVID-19. The trial considered the effect of a maximum targeted dose of 600 μg/kg daily for 6 days. An earlier arm of the trial found no effect of 400 μg/kg, daily for 3 days. The investigators concluded:
ACTIV-6 trial "outcomes" the clearest proof yet that obfuscation is still the best way of hiding the truth: IVERMECTIN works for every stage of Covid-19, starting with blanket global prophylaxis.
ACTIV-6 trial "outcomes" the clearest proof yet that obfuscation is still the best way of hiding the truth: IVERMECTIN works for every stage of Covid-19, starting with blanket global prophylaxis.